ClinicalTrials.gg
Active, not recruitingNCT03907527Updated Nov 8, 2024

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Phase 1 interventional study of PRGN-3005 UltraCAR-T cells and PRGN-3005 UltraCAR-T cells in Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, sponsored by Precigen, Inc. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Precigen, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 589 studies in Fallopian Tube Neoplasms with a site in United States — 61 open to participants now, 130 under way, 24 of them phase 3. Fallopian Tube Neoplasms · United States.

Planned enrollment
177th of 513
71 · median 40
Started
2019
with 28 others
Phase 1
181 of 589
14 open now
Primary completion
2024-12
later than 24 of 129 live
Registered
452nd of 589
by date

Among the 589 studies in Fallopian Tube Neoplasms with a site in United States, this one is the 177th largest by planned enrollment of the 513 interventional ones that give a count, is one of 29 that started in 2019, is one of 181 in phase 1, reaches primary completion later than 24 of the 129 other live ones, and was the 452nd registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

61 of the 589 studies in Fallopian Tube Neoplasms with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 589 studies in Fallopian Tube Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.

03

Conditions studied

  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Refractory Fallopian Tube Carcinoma
  • Refractory Ovarian Carcinoma
  • Refractory Primary Peritoneal Carcinoma
  • Stage III Fallopian Tube Cancer AJCC V8
  • Stage III Ovarian Cancer AJCC V8
  • Stage III Primary Peritoneal Cancer AJCC V8
  • Stage IIIA Fallopian Tube Cancer AJCC V8
  • Stage IIIA Ovarian Cancer AJCC V8
  • Stage IIIA Primary Peritoneal Cancer AJCC V8
  • Stage IIIA1 Fallopian Tube Cancer AJCC V8
  • Stage IIIA1 Ovarian Cancer AJCC V8
  • Stage IIIA2 Fallopian Tube Cancer AJCC V8
  • Stage IIIA2 Ovarian Cancer AJCC V8
  • Stage IIIB Fallopian Tube Cancer AJCC V8
  • Stage IIIB Ovarian Cancer AJCC V8
  • Stage IIIB Primary Peritoneal Cancer AJCC V8
  • Stage IIIC Fallopian Tube Cancer AJCC V8
  • Stage IIIC Ovarian Cancer AJCC V8
  • Stage IIIC Primary Peritoneal Cancer AJCC V8
  • Stage IV Fallopian Tube Cancer AJCC V8
  • Stage IV Ovarian Cancer AJCC V8
  • Stage IV Primary Peritoneal Cancer AJCC V8
  • Stage IVA Fallopian Tube Cancer AJCC V8
  • Stage IVA Ovarian Cancer AJCC V8
  • Stage IVA Primary Peritoneal Cancer AJCC V8
  • Stage IVB Fallopian Tube Cancer AJCC V8
  • Stage IVB Ovarian Cancer AJCC V8
  • Stage IVB Primary Peritoneal Cancer AJCC V8

Keywords

  • Platinum resistant
  • Ovarian Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer that have progressed after receiving standard of care therapies or are not eligible to receive available therapies with known clinical benefit will be eligible for the study. Patients must have that can be accurately measured by 1.1 criteria in at least one dimension as >= 1.0 cm or > 1.5 cm lymph node with computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) techniques.

    • Platinum resistant is defined as progression of disease within six months of platinum regimen.
    • Patients with BRCA mutations who have completed standard therapies (including PARP inhibitors) are allowed on this study.
  • Patients must be capable of understanding and providing a written .
  • Patients must be 14 days from previous cytotoxic chemotherapy at time of cell collection.
  • Laboratory values must indicate adequate organ function.
  • Patients must be at least 28 days post systemic prior to enrollment except as premedication for contrast allergy and/or other protocol-mandated medication.
  • Patients must have (ECOG) performance status score of =\< 2.
  • Patients must have recovered from major acute infections and/or recent surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment.
  • Negative pregnancy test for women of . Women of childbearing potential are those who have not been surgically sterilized, are \< 60 years old, or have had menses within the past 12 months.
  • Women of childbearing potential must be willing to use 2 methods of before, during, and at least 4 months after the PRGN-3005 cell infusion.

Exclusion criteria

Exclusion Criteria:

  • Patients with any of the following cardiac conditions:

    • Symptomatic restrictive cardiomyopathy
    • Unstable angina or symptomatic coronary artery disease within 4 months prior to enrollment
    • functional class III-IV heart failure on active treatment
    • Symptomatic pericardial effusion
    • Congestive heart failure
    • hypotension.
  • Patients with CA 125 =\< during screening.
  • Patients with history of (HIV), West Nile, Zika, or active or C infections.
  • Patients with severe, symptomatic ascites requiring diuretics, regular paracentesis, or other invasive interventions.
  • Patients within 28 days of receiving another agent.
  • Patients with pulmonary hypertension, pulmonary fibrosis, or restrictive lung disease, patients with baseline oxygen saturation on room air \< 92%, (FEV1) =\< 50%, or diffusion capacity of the lung for carbon monoxide (DLco) (corrected) of \< 40% will be excluded.
  • Women who are pregnant or breast feeding.
  • Patients with second within the last 5 years excluding basal carcinoma of the skin, squamous carcinoma of the skin, or in situ cervical dysplasia that has undergone curative therapy.
  • Patients with an active disease requiring therapy or uncontrolled with treatment.
  • Patients who are simultaneously enrolled in any other treatment study.
  • Clinical or radiological evidence of acute bowel obstruction within 30 days of signing consent.
  • Patients with known or treated .
  • Patients with an active seizure disorder.
  • Any female patient \<60 years old who does not meet at least one of the following criteria will be considered to have :

    • for at least 12 consecutive months (i.e., no menses), or
    • Undergone a sterilization procedure (hysterectomy, salpingectomy, or bilateral oophorectomy; tubal ligation is not considered a sterilization procedure). Pregnancy test for females of reproductive potential must be negative within 14 days before leukapheresis.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Experimental
    Treatment (PRGN-3005 UltraCAR-T cells) IP Administration

    Patients receive autologous PRGN-3005 UltraCAR-T cells via IP administration with or without lymphodepleting chemotherapy.

    Biological: PRGN-3005 UltraCAR-T cells

  • Experimental
    Treatment (PRGN-3005 UltraCAR-T cells) IV Administration

    Patients receive autologous PRGN-3005 UltraCAR-T cells via IV administration with or without lymphodepleting chemotherapy.

    Biological: PRGN-3005 UltraCAR-T cells

Interventions

  • BiologicalPRGN-3005 UltraCAR-T cells

    Given IP

  • BiologicalPRGN-3005 UltraCAR-T cells

    Given IV

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events

    Time frame: Up to 12 months after infusion

  2. Maximal tolerated dose of PRGN-3005

    Will be determined by a 3 X 3 dose escalation study for both intraperitoneal infusion and intravenous infusion of the trial.

    Time frame: Up to 28 days

Secondary outcomes

  1. Evidence of anti-tumor activity

    Graded according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    Time frame: Up to 5 years

  2. Number of PRGN-3005 T Cells

    Number of PRGN-3005 T Cells present in patients treated with PRGN-3005

    Time frame: Up to 12 months post treatment

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Dec 2024, 67 months after the start.

Of 31 industry-sponsored phase 1 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 57. This study's planned 67 months is above that.

Counting every sponsor, half of 97 studies reached it within 54 months; a quarter within 36 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2019
First posted
Apr 9, 2019
StartActual
Apr 30, 2019
Primary completionEst.
Dec 15, 2024
CompletionEst.
Nov 15, 2028
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03907527
Lead sponsor
Precigen, Inc
Responsible party
Sponsor
First posted
Apr 9, 2019
Start date
Apr 30, 2019
Primary completion
Dec 15, 2024 (estimated)
Completion
Nov 15, 2028 (estimated)
Last update
Nov 8, 2024

Study contacts

Amy R. Lankford, PhD
study director · Precigen, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion